Journal Archive

Editorial

The Future of Gene Therapy for Rare Eye Diseases

Spotlight Article

Interview

Rare Diseases – Clinical & Commercial Developments

Dr Girach

PROFESSOR ANIZ GIRACH qualified as an Ophthalmologist (with a specialty in Retina) and worked in Cambridge (UK). After spending 11 years in the NHS, he joined the pharmaceutical industry with Eli Lilly, focusing on retinal diseases. He has in total 22 years of industry experience in roles with Merck (as their Global Head of Ophthalmology) and Alcon, where he was Vice President of Clinical Development, and ThromboGenics, where he was the Global Head of Ophthalmology/Chief Medical Officer overseeing the development and approval of Ocriplasmin (Jetrea) — a first in class biologic therapy for retinal disease. In addition to an Honorary Professorship at Wills Eye Hospital (Philadelphia, USA), he was recently the Chief Medical Officer at Nightstar Therapeutics, overseeing the development of gene therapies for inherited retinal diseases. He is a member of three Scientific Advisory Boards for international ophthalmic organizations currently, and reviewer for five peer-reviewed journals, including Eye and IOVS. He has edited four books and published over 60 abstracts/manuscripts in peer-reviewed journals in Ophthalmology, with numerous invited lectures at national/international ophthalmology meetings. His special interests are medical retina, vitreomacular interface abnormalities, inherited rare retinal diseases and gene therapy.

DOI: 10.18609/cgti.2018.073
Citation: Cell Gene Therapy Insights 2018; 4(7), 725-731.
Open access

Read the full article »

Developing Gene Therapy for CEP290-Associated Retinal Ciliopathies

Spotlight Article

Editorial

Hemant Khanna

Rare Diseases – Clinical & Commercial Developments

Dr. Hemant Khanna obtained his Ph.D. in 2001 from the Institute of Genomics and Integrative Biology, University of Delhi, India. His lab investigates molecular and cell biological bases of cilia-dependent photoreceptor degenerative disorders, such as Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA; childhood blindness disorder). His studies have resulted in the development of new therapeutic strategies for both RP and LCA. The Khanna lab uses zebrafish, mouse mutants, human fibroblasts and iPSC-derived tissues as platforms to model and understand human blinding diseases. The Khanna lab is also a member of the Horae Gene Therapy Center and Li Weibo Rare Disease Institute at the University of Massachusetts Medical School (https://www.umassmed.edu/khannalab/).

DOI: 10.18609/cgti.2018.066
Citation: Cell Gene Therapy Insights 2018; 4(7), 647-652.
Open access

Read the full article »

Interview

Advancing the Development of AAV-Based Gene Therapy for Rare Diseases

Spotlight Article

Interview

SUYASH PRASAD

Rare Diseases – Clinical & Commercial Developments

Prasad

DR SUYASH PRASAD has served as Senior Vice President and Chief Medical Officer of Audentes Therapeutics, a San Francisco-based biotech company, since February 2014. He has a wide range of experience and achievement in international drug development from early pre-clinical stages into clinical trials spanning Phase I to IV, with a specific focus on the development of therapies to treat rare paediatric disorders. Dr Prasad has held positions of increasing responsibility at BioMarin Pharmaceutical, Inc., Genzyme Corporation and Eli Lilly and Company. He graduated in Medicine at the University of Newcastle-upon-Tyne, UK, where he received commendations for Paediatrics, Obstetrics and Gynecology and Medical Ethics. He is a UK board certified physician and is a member of the Royal College of Physicians (MRCP) and the Royal College of Paediatrics and Child Health (MRCPCH). Dr Prasad received his Diploma in Pharmaceutical Medicine from the Royal College of Physicians of the United Kingdom and his Masters in Translational Science from Kings College, London. He is a Fellow of the Faculty of Pharmaceutical Medicine (FFPM) and is a past recipient of the Outstanding Contribution Award from the Faculty of Pharmaceutical Medicine of the UK Royal College of Physicians. Dr. Prasad currently sits on the board of the National PKU Association.

DOI: 10.18609/cgti.2018.065
Citation: Cell Gene Therapy Insights 2018; 4(7), 671-678
Open access

Read the full article »


The Critical Role of Patient Advocacy Groups in the Development of Rare Disease Gene Therapies

Spotlight Article

Interview

Susan Wilson & Elisabeth Linton

Rare Diseases – Clinical & Commercial Developments

SUSAN WILSON co-founded The Children’s Medical Research Foundation with her husband Brad in 1995. Prior to this, Sue had over 17 years of business experience growing from administrative assistance to office management and finally to assisting in structuring and management of the office for a start up company. All of these experiences helped her in forming the Foundation and moving it toward its mission of a cure for Sanfilippo Syndrome.

ELISABETH LINTON left her career as a food stylist and consultant to co-found The Sanfilippo Children’s Research Foundation (SCRF) with her husband Randall after their youngest child Elisa was diagnosed with Sanfilippo syndrome in 1998. Through Elisabeth’s leadership almost $8 million has been committed to research worldwide sponsoring over 37 research projects in 6 countries and establishing The Elisa Linton Sanfilippo Research Laboratory at Sainte Justine Children’s Hospital, Montreal Quebec, Canada. The SCRF has funded groundbreaking work that is pushing the field of childhood disability research forward in a significant way—and showing enormous promise for saving lives and easing the difficulties faced by severely disabled Sanfilippo children and their families. Her greatest joy has been raising her children, Jessica, Connor and Elisa with her husband and recently becoming a grandma to Chloe. She is grateful for the support of those who have helped her make a positive impact for Sanfilippo children and their families, and plans to continue the efforts of The SCRF, even in light of Elisa’s passing away Oct. 31st, 2016.

DOI: 10.18609/cgti.2018.066
Citation: Cell Gene Therapy Insights 2018; 4(7), 665-672.
Open access

Read the full article »

SR-TIGET: Continuing to Drive Enabling Technology Development & Clinical Innovation in Rare Diseases

Spotlight Article

Interview

Rare Diseases – Clinical & Commercial Developments

Alessandro Aiuti

Alessandro Aiuti initially focused his research studying diseases of the coagulation and HIV infection. His research on hematopoietic stem cells (HSCs) led to the discovery of the first chemokine produced by bone marrow cells inducing migration of human HSCs. His current research is focused on pediatric hematology and immunology and specifically on primary immunodeficiencies, genetic diseases of the immune system. He pioneered the successful gene therapy clinical trial for SCID patients that lack adenosine deaminase (ADA), a fatal disorder of purine metabolism and immunodeficiency. This clinical trial, now completed, introduced a conditioning regimen to favor the engraftment of gene corrected cells and is considered to be among the most important clinical result of gene therapy for genetic diseases. Gene therapy for ADA SCID has been designated as Orphan Drug in Europe and USA. His most recent research with HSCs transduced with lentiviral vectors led to the successful application of therapy for another primary immunodeficiency, Wiskott-Aldrich syndrome.

DOI: 10.18609/cgti.2018.069
Citation: Cell Gene Therapy Insights 2018; 4(7), 719-724.
Open access

Read the full article »

Leukodystrophies: a Patient Advocacy Perspective

Spotlight Article

Interview

Rare Diseases – Clinical & Commercial Developments

Maria Kefalas

MARIA KEFALAS PhD is the co-founder and executive director of the Calliope Joy Foundation, a Philadelphia, PA based charity that advocates for children and families impacted by leukodystrophies. She has published essays about her life caring for her daughter, Callie, who has metachromatic leukodystrophy, in Slate, The Huffington Post, and STAT. Her advocacy for gene therapy was featured on CBS Sunday Morning with Jane Pauley. Ms. Kefalas is writing a memoir titled Investing in Miracles (Beacon Press, forthcoming) about her journey as a parent advocate. Cal is 8 years old and receives hospice care. But thanks to her doctors and nurses, Cal still laughs and smiles every day.

DOI: 10.18609/cgti.2018.075
Citation: Cell Gene Therapy Insights 2018; 4(7), 705-713
Open access

Read the full article »

Expert Insight

Gene replacement therapy for hemoglobinopathies: clinical benefit & challenges for widespread utilization

Spotlight Article

EXPERT INSIGHT

Marina Cavazzana, Annarita Miccio, Isabelle Andre-Schmutz & Fulvio Mavilio

Rare Diseases – Clinical & Commercial Developments

β-thalassemia and sickle cell disease (SCD), the most common genetic disorders worldwide, are caused by mutations affecting quantitatively or qualitatively hemoglobin β-chain production. With the advent of β-globin expressing lentiviral vectors (LVs), transplantation of autologous, genetically modified hematopoietic stem cells (HSCs) holds the promise of eliminating the morbidity and mortality associated with allogenic HSC transplantation and circumventing the need for suitable donors. LV-based gene addition strategies have shown safety and efficacy in both β-thalassemia and SCD patients. Despite these promising results, gene therapy still requires significant development to become standard clinical practice. Here, we discuss several issues that limit the efficacy and the utilization of LV-based gene therapy approaches for β-hemoglobinopathies, such as the source and the quality of HSCs, the choice of the optimal conditioning regimen, the cell manufacturing process and the regulatory framework.

Submitted for review: Jul 13 2018 Published: Oct 15 2018
DOI: 10.18609/cgti.2018.063

Citation: Cell Gene Therapy Insights (7) 653-664.
Open access

Read the full article »

Innovator Insight

Development of purification steps for several AAV serotypes using POROS™ CaptureSelect™ AAVX affinity chromatography

Spotlight Article

Innovator Insight

M Toueille, L Dejoint, E Attebi, J Cartigny, C Rasle, S Potier, S Rundwasser, L Guianvarc’h, C Lebec & M Hebben

latest advances in BIOPROCESSING: overcoming bottlenecks

Genethon is an integrated R&D centre created in 1990 by the French Association of Muscular Dystrophy. The Centre performs both gene therapy translational research and clinical development, with a specific focus on rare genetic diseases such as neuromuscular disorders, immuno-deficiencies, eye diseases and liver diseases. The two main vector platforms used at Genethon are AAV and lentiviral vectors.

Published: Sept 18 2018
DOI: 10.18609/cgti.2018.061
Citation: Cell Gene Therapy Insights 4(7), 637-645
Open access

Current purification methods for viral vector manufacturing usually involve multiple steps of chromatography, for example ion exchange and hydrophobic interaction, which leads to cumulative yield loss and ultimately, increased cost.

Thermo Fisher’s CaptureSelect™ technology addresses this issue by providing high-affinity binding ligands for affinity chromatography. This approach provides high purity and productivity in fewer steps than traditional purification processes, while also offering process consistency and scalability.

The technology is based on the utilisation of the variable domains of camelid heavy-chain-only antibodies (VHH) which offer full functionality in antigen-specific recognition and also high-affinity binding (the three CDR regions of the VHH ligand provide unique, tunable specificity). Due to their compact structure, the domains are highly robust and capable of withstanding the various conditions typical of chromatography runs. Additionally, the selected ligands have the advantage of being produced in an animal origin-free system – Saccharomyces cerevisiae (baker’s yeast).

The result is a unique screening technology for target specificity, mild elution and stability, which is designed for commercial purification processes.

To read the full article, simply complete the form below and click submit.

Read the full article »

Research Article